Replies to post #445922 on Anavex Life Sciences Corp (AVXL)

[bas2020]

You're talking to a known FUDster. Beware!

[mike_dotcom]

I am NOT laughing at your post. We're all living that reality. Missling comes off as an awesome Bullschitt artist, constantly setting goals and NEVER delivering. I really thought the Rett data was going to be great and lead to a higher stock price. My bad. Any little gain the stock now is sold heavily so we have lower highs and lower lows. I can't see anything on the horizon to change things. Now even the publication of the peer review scares me. Everybody assumes that it is going to be positive. What if it is not?

[BIOChecker4]

You’re welcome.

As you’ve already seen just by reading this board, Anavex is very controversial. However, there are posters here who totally believe in the CEO and have no tolerance for anyone who dares to question his behavior or his truthfulness (bas2020, Hoskuld, Nidan, XenaLives, who is in a class by herself, and Georgejjl in particular but not just them) and those like me who are hopeful about the science but question the CEO’s honesty and competence based on the his stumbles, fumbles, misstatements, missed timelines, cherry picking of data, goal post moving, terrible communications, use of a vulture investor to finance the company, and questionable career track record (which you can research online).

Good luck with your investment.

[crescentmotor]

he [Tom Bishop] continues to believe that this company will eventually produce an approval that could help tons of people, and dang sure help my portfolio, so I ride it out and buy more.

Believe me when I say a lot of AVXL investors are discouraged by the recent Rett news and the reality that commercial revenues will not be forthcoming, at least in 2024, and perhaps never. But you are not alone in recognizing the potential that still may be achieved. On the day the EXCELLENCE trial failure was announced, I increased my AVXL long call options holdings (ITM and near ITM) by 33% because I deemed the price haircut to be an over reaction considering the big picture; that is, AD. This happened even though I had increased those same holdings by 32% in December on the news about the favorable AD 2-73 developments in the European Union, specifically the anticipation of filing an MAA. Many of us are feeling more optimistic these days about the potential for regulatory approval of Blarcamesine for AD starting in the European Union as we also anxiously await the peer review journal article in the U.S.